Accenture Health Feed

North American Pharmaceutical Company: Decision-Making Effectiveness Program

Tue, 16 Dec 2008 02:26:00 GMT

This North American pharmaceutical company was experiencing dramatic growth and strategic shifts in its business, which were leading to an increasingly complex organizational structure. The company needed to improve its decision-making processes in order to respond more effectively to competitive pressures and tackle organizational complexity and multiple marketplace demands. Both the executive team and employees of the company identified decision making as a focus for improvement. The executive team targeted "effective and timely decision making” as one of eight strategic imperatives to achieve the company’s vision.

Biosimilars: Emergence of a Third Market Dynamic Between Original Products and Generics

Wed, 17 Jun 2009 06:23:00 GMT

Biotechnologically produced drugs, so called biologics, are a major growth driver for the global pharmaceutical market. In 2007 the biologics market grew noticeably faster than the overall market; with a double-digit growth of 20 percent, they generated $95 billion of sales amounting to approximately 15 percent of global pharma revenues.

Sustaining High Performance through Customer Centricity: How Customer-Centric Business Models Drive Growth for Pharmaceutical Companies

Fri, 30 Oct 2009 05:51:00 GMT

At a time when the pharmaceutical industry is being affected by a challenging business environment, an altering marketplace and a changing customer landscape, the need for pharma companies to focus more intently on customers is more crucial than ever.

In Pursuit of High Performance: Understanding Pharmaceutical Research and Development Cost Drivers

Tue, 07 Aug 2007 18:18:59 GMT

While the pharmaceutical and biotechnology industry continues to revolutionize how diseases are studied, treated, cured and prevented, the cost to develop the world's therapies continues to rise. Various experts have reported different estimates on the exact cost, but there seems to be consensus that the increase of these costs has been significant over the past five years. Further, there is overall agreement and evidence to support the fact that these increases will continue.

Innovation for Growth: How Life Science Companies Can Realize High Performance by Driving Growth through Innovation

Thu, 11 Dec 2008 02:32:00 GMT

To address life sciences industry challenges, it is imperative to reinforce innovation management, one of the most complex activities at any organization. Today, life sciences companies not only face severe gaps in product pipelines, regulatory obstacles and potential late-stage failures of promising blockbuster drugs, but also increasing competition from biotech and generics companies. Therefore, companies must broaden their view of innovation and develop a framework that Accenture calls “corporate innovation capability.”

Helping an Integrated Health System Achieve High Performance with a Leading-edge Electronic Medical Records Capability

Thu, 17 Sep 2009 08:29:00 GMT

The integrated health system is part of a larger non-profit health system that purchased a number of clinical information system applications and modules from Cerner Corporation to enable the creation of an Electronic Medical Record (EMR) that would integrate elements of a patient’s health history, medication information, test results and treatment plans in an electronic format.

Achieving High Performance through Implementation of Health Information Exchange Networks

Fri, 28 Aug 2009 09:33:00 GMT

Download the full report [PDF, 3.5MB] PDF Help

Health Plans: Achieving High Performance in Uncertain Times

Mon, 28 Sep 2009 06:18:00 GMT

Unprecedented uncertainty in the health plan industry creates threats and opportunities for leaders. Despite obstacles, health plans can achieve high performance. The baseline step for all health plans is to fully reexamine their administrative and medical costs to drive significant near-term savings. Improving administrative and medical cost performance will enable health plans to compete in the present while investing for the future. Health care reform is likely to open up the largest untapped domestic market ever, but it will require capital and new capabilities to capture the opportunity.

Health Plans: Achieving High Performance in Uncertain Times

Thu, 30 Jul 2009 06:10:00 GMT

A New View of What is Possible for Health Care Payers

Fri, 16 Jan 2009 04:05:00 GMT

Download the full article—A New View of What's Possible for Health Care Payers [PDF, 444KB] PDF Help

India’s Potential as Part of a Global Pharmaceutical Value Chain

Wed, 07 Oct 2009 07:08:00 GMT

For this study, Accenture conducted more than 20 focus interviews with senior executives of global pharmaceutical organizations already active in India. All interviewees hold senior positions in production, marketing, distribution or strategic planning based in India, Europe and the United States. The intent of the study is to capture as accurate and complete a picture of India’s pharmaceutical opportunity as possible.

Top Issues Facing Health Payers in 2007 and 2008

Tue, 07 Aug 2007 18:24:23 GMT

The most significant pressures facing payers evolve constantly, though they rarely change radically from year to year. While payers strive to lower administrative costs and improve efficiencies, manage health care costs and grow the business, recent years have seen substantial change in how they address these issues.

State of Tennessee: Clinical Data Exchange

Tue, 16 Sep 2008 21:54:47 GMT

For several years, the state of Tennessee’s TennCare provided a model for health care reform. Unfortunately, TennCare's success quickly unraveled due to soaring health care costs, a rise in its numbers of Medicaid recipients and uninsured residents, and a corresponding decline in revenues. To address these challenges, Tennessee Governor Phil Bredesen believed improved information-sharing among health care providers and key stakeholders might alleviate some of the cost burden without sacrificing service quality.

State of Tennessee: Clinical Data Exchange

Thu, 25 Sep 2008 21:16:18 GMT

MedShare: Supply Chain Strategy

Tue, 07 Aug 2007 18:21:45 GMT

For MedShare, a nonprofit dedicated to distributing surplus medical equipment to countries around the world, supply chain excellence is truly a key driver of high performance. Accenture helped MedShare develop a new supply chain strategy to expand its good work.

Leading Health Benefits Company: Enterprisewide e-Business Capabilities

Wed, 08 Jul 2009 03:44:00 GMT

This leading health benefits company is the product of a series of mergers. In the years leading up to these mergers, the company had successfully positioned itself as a leader in the insurance industry. Based on this long history of successful expansion, the organization clearly understands the importance of managing growth while maintaining a clear market focus. Equally important, the company understands the challenges that can accompany mergers and acquisitions—particularly the need to maintain a high standard of customer service amid the blending of operations, systems and services.

Savvy Firms Can Find Opportunities in the Current Economic Crisis

Thu, 28 May 2009 04:24:12 GMT

By Catherine Bolgar

The Christ Hospital: Infrastructure Transformation

Wed, 22 Jul 2009 08:06:00 GMT

The Christ Hospital selected Accenture to lead the ambitious transformation program due to its breadth and depth of knowledge, skills and capabilities in hospital operations, building and integrating enterprise-wide operational functions and supporting infrastructure processes and IT systems. In addition, Accenture brought valuable insights from its ongoing High Performance Business research, in-depth knowledge of the health care industry and unrivaled experience and capabilities in managing large-scale, complex transformation programs.

Confronting the Future: Getting High Performance Back into the Biopharmaceutical Industry

Thu, 11 Jan 2007 19:07:07 GMT

The biopharmaceutical industry is facing a "perfect storm" of new challenges—patent expirations, generic competition, falling R&D productivity, pricing pressures and hostile regulatory environments. Given these difficulties, it's no surprise that in the last few years, financial investors have punished the industry and wiped US$500 billion off the balance sheets of big biopharmaceutical companies.

Achieving High Performance through Product Launch Management

Tue, 23 Jun 2009 02:26:00 GMT

Launching products into the pharmaceutical market has never been more crucial and challenging for life science companies seeking to achieve high performance. A product launch nowadays has to be "faster" (enhanced uptake of top line sales), "better" (accelerated growth and higher peak sales) and "cheaper" (executed with fewer resources).

Five Steps towards Building an Effective Compliance Capability

Thu, 24 May 2007 16:56:41 GMT

In this article for Drug & Market Development magazine, Mark LaLeike, partner with Accenture's Health & Life Sciences industry group, discusses the challenges compliance leaders face to align their priorities with those of general and commercial management.

The American Public on Health Care: The Missing Perspective

Wed, 19 Nov 2008 06:26:00 GMT

Health care is one of the most pressing issues on the minds of Americans today. It’s at the center of debate at every level of the political arena, and is one of the United States’ most critical public policy concerns.

Making the Right Bets: How to Identify Pharmaceutical Deals Worth Doing

Wed, 20 Aug 2008 18:30:57 GMT

Until now, there has been no quantitative information pharmaceutical companies can use to select and structure deals that are likely to succeed. Pharmaceutical industry experts have relied largely on qualitative evidence and experience-based generalizations in putting together licensing or collaborative arrangements.